Abbott Launches U.S. Endovascular Unit

The establishment of U.S. commercial operations of its Endovascular Technologies business unit has been announced by Abbott Vascular Devices (Redwood City, CA, USA), a division of Abbott Laboratories (Abbott Park, IL, USA).

The Vascular Devices division will include the Coronary Technologies unit and the Vessel Closure Technologies unit, with a portfolio of products to assist clinicians in treating noncoronary vascular disease. These include products used at various times in a diagnostic or interventional procedure, whether for vessel dilation, stent placement, or site closure. The launch of the Vascular Devices division has been coupled with the launch of four products: the Xceed nitinol self-expanding biliary stent, the Xpert self-expanding biliary stent, the Fox percutaneous transluminal angioplasty (PTA) catheter, and the Prostar XL suture-mediated closure device. The Xceed and Xpert stents have recently been cleared by the U.S. Food and Drug Administration (FDA), while the other two products had previously been cleared.

"With the establishment of commercial operations in the United States of our Endovascular Technologies unit we are ready to provide cutting-edge products that meet the needs of U.S. clinicians and their patients,” said Robert B. Hace, president, Abbott Vascular Devices.





Related Links:
Abbott Vascular Devices